Industry reports 48 deals worth $3 billion in Oct 2021: GlobalData

In October 2021, the healthcare industry reported 48 deals worth $3 billion as compared to the last 12-month average (October 2020 to September 2021) of 99 deals worth $25.9 billion, a report from GlobalData said.

Pacira Biosciences Inc to acquire Flexion Therapeutics Inc for approximately $630 million; Shanghai Fosun Pharmaceutical (Group) to acquire 73 per cent stake in Chengdu Antkin Biotechnology for $627.3 million; and Supernus Pharmaceuticals to acquire Adamas Pharmaceuticals for $450 million, were the three major deals that contributed 56.4 per cent of the total deal value during October 2021.

The healthcare industry reported 91 venture capital (VC) deals worth $2.7 billion in October 2021, compared to the last 12-month average (October 2020 to September 2021) of 168 deals worth $5.1 billion.

Neumora Therapeutics Inc raising $400 million in series A round of financing to develop targetted therapies for brain diseases; CinCor Pharma Inc raising $143 million in Series B financing to support the continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate in development for the treatment of hypertension, primary aldosteronism and chronic kidney disease; and Cambrian Biopharma Inc raising $100 million in series C financing to advance healthspan-boosting therapeutics to the clinic, were the major VC deals reported in October 2021.